UK markets closed
  • FTSE 100

    +6.23 (+0.08%)
  • FTSE 250

    +180.74 (+1.00%)
  • AIM

    +1.20 (+0.17%)

    -0.0015 (-0.13%)

    -0.0005 (-0.04%)
  • Bitcoin GBP

    -19.44 (-0.09%)
  • CMC Crypto 200

    +0.90 (+0.15%)
  • S&P 500

    -11.65 (-0.27%)
  • DOW

    -158.84 (-0.47%)

    -0.94 (-1.02%)

    -14.00 (-0.75%)
  • NIKKEI 225

    -14.90 (-0.05%)

    +436.63 (+2.51%)
  • DAX

    +63.08 (+0.41%)
  • CAC 40

    +18.82 (+0.26%)

Sweden Diabetes Market Report 2023: Featuring B. Braun Melsungen, Eli Lilly, Novo Nardisk, Becton, Dickinson, Medtronic & More

Company Logo
Company Logo

Swedish Diabetes Market

Swedish Diabetes Market
Swedish Diabetes Market

Dublin, March 07, 2023 (GLOBE NEWSWIRE) -- The "Sweden Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to's offering.

Sweden's Diabetes Market will reach US$ 1.86 Billion in 2028 and expand at a CAGR of 4.26% from 2023 to 2028, according to the publisher. Diabetes is obtaining epidemic proportions, and digital health companies are fighting back with innovative solutions.

According to World Diabetes Organization, diabetes presently affects 59.8 million individuals in Europe, which will rise to 73.8 million by 2040. Diabetes is currently one of the most critical emergencies in global health and shows an increasing prevalence in Sweden.

The healthcare system of Sweden has taken a heavy toll due to diabetes, which could be due to the associated direct costs required for medical management. Nowadays, caring for people with Type 2 diabetes has expanded from including only GPs to involving RNs in the main workforce. In Sweden, PHCCs have diabetes-responsible GPs and RNs available in-house who have the overall responsibility for the care and treatment of people with T2DM. According to the publisher, the Sweden Market was US$ 1.45 Billion in 2022.

Type 2 diabetes is a heterogeneous disease in Sweden

Diabetes mellitus is recognized as an epidemic. The prevalence of type 2 diabetes is increasing dramatically in Sweden, with projections of even higher growth over the coming decades. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs. At any age, increasing weight raises the risk of type 2 diabetes. In people who are obese, type 2 diabetes is three to ten times more common than it is in people of average weight. Moreover, over the past decades, childhood-onset type 1 diabetes has been reported to be increasing in Sweden.

Insulin Pen will grow at a High Rate and Capturing the Highest Market Share in the Coming Years

The Sweden Diabetes Market by the device is segmented into; SMBG, CGM, Insulin Pumps, and Insulin Pens. Insulin cartridges in reusable pens are an upgraded version of insulin vials. Significant types of insulin are manufactured in the form of cartridges, which makes them easily attainable. These devices have all the functional advantages of reusable pens and are economical, as these cartridges are less costly than disposable insulin pens in the long run. Due to the rising demand for insulin cartridges, most insulin device manufacturers have produced reusable insulin pens compatible with various manufacturers' cartridges. These insulin cartridges are more consumer-friendly, as they are smaller and less observable than the classic vial-and-syringe. These devices are also more portable for consumers on the go.

Moreover, the SMBG segment also holds a significant market share. Driving factors that help to reach this market are the increasing diabetic population in Sweden, Governments, and NGOs' efforts to increase awareness, increasing per capita healthcare expenditure, and availability of reimbursements.

Key Players:

The major players competing in the Sweden Diabetes Market are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.

In May 2021, Medtronic announced the CE Mark for expanded functionality of the company's In Pen smart insulin pen for multiple daily injections (MDI).

In May 2021, Medtronic secured European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either utilized as a standalone continuous glucose monitor or combined into Medtronic's insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.

Segments Market based on Devices

1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump

Sweden Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)

1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement


1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement

3. Insulin Pen Market

1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies

4. Insulin Pump Market

1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies

Report Attribute


No. of Pages


Forecast Period

2022 - 2028

Estimated Market Value (USD) in 2022

$1.45 Billion

Forecasted Market Value (USD) by 2028

$1.86 Billion

Compound Annual Growth Rate


Regions Covered


Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

5. Sweden Diabetes Market

6. Sweden Diabetes Population

7. Sweden Diabetes Market Share Analysis

8. Continuous Glucose Monitoring Market (CGM) - Market & Users

9. Blood Glucose Device (SMBG) -Sweden Market & Users

10. Insulin Pen -Sweden Market & User Analysis

11. Insulin Pump - Sweden Market & Users

12. Insulin Pen - Company Analysis

13. Insulin Pump - Company Analysis

14. SMBG - Company Analysis

15. CGM - Company Analysis

Companies Mentioned

  • B. Braun Melsungen AG

  • Eli Lilly and Company

  • Terumo Corporation

  • Becton, Dickinson (BD)

  • Novo Nardisk

  • Ypsomed AG

  • Medtronic

  • InsuletCororation

  • Abbott Laboratories

  • DarioHealth Crop

  • Dexcom, Inc

  • Roche Diagnostic

  • Tandem Diabetes Care

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900